Abstract: The present invention provides methods for the treatment or prevention of allergic airways diseases, the suppression of allergic immune responses, and the induction protective immunity against allergic airways diseases wherein the methods comprise administering to subjects in need thereof an effective amount of a Streptococcus pneumoniae capsular polysaccharide and a Streptococcus pneumoniae exotoxin or exotoxoid, optionally together with one or more additional antigenic or immunomodulatory constituents, components or fractions of Streptococcus pneumoniae and/or immunopotentiators. Administration of individual components is also contemplated. Also provided are vaccine compositions suitable for use in accordance with methods disclosed herein.

Abstract: The present invention provides methods for the treatment or prevention of allergic airways diseases, the suppression of allergic immune responses, and the induction protective immunity against allergic airways diseases wherein the methods comprise administering to subjects in need thereof an effective amount of a Streptococcus pneumoniae capsular polysaccharide and a Streptococcus pneumoniae exotoxin or exotoxoid, optionally together with one or more additional antigenic or immunomodulatory constituents, components or fractions of Streptococcus pneumoniae and/or immunopotentiators. Administration of individual components is also contemplated. Also provided are vaccine compositions suitable for use in accordance with methods disclosed herein.

Abstract: The present invention provides a method for the treatment or prevention of an allergic airways disease in a subject, the method comprising administering to the subject a composition comprising Streptococcus pneumoniae or one or more antigens derived therefrom. Also provided are methods and compositions for inducing protective immunity against an allergic airways disease, suppressing an allergic immune response, and treating or preventing conditions such as eosinophilia, mucous secreting cell expression, airway hyperresponsiveness and Th2-mediated disease.

Abstract: Protein antigens from Streptococcus pneumoniae are disclosed, together with nucleic acid sequences encoding them. Their use in vaccines and in screening methods is also described.

Abstract: Novel proteins from Streptococcus pneumoniae are described, together with nucleic acid sequences encoding them. Their use in vaccines and in screening methods is also described.

Abstract: Novel protein antigens from Streptococcus pneumoniae are disclosed, together with nucleic acid sequences encoding them. Their use in vaccines and in screening methods is also described.